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Abstract 
 
Obesity, one of the main causes of metabolic syndrome (MetS), is an increasingly common 
health and economic problem worldwide, and one of the major risk factors for developing 
type 2 diabetes and cardiovascular disease. Chronic, low-grade inflammation is associated 
with MetS and obesity. A dominant type 2/anti-inflammatory response is required for 
metabolic homeostasis within adipose tissue: during obesity, this response is replaced by 
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infiltrating, inflammatory macrophages and T cells. Helminths and certain protozoan 
parasites are able to manipulate the host immune response towards a TH2 immune phenotype 
that is beneficial for their survival and there is emerging data that there is an inverse 
correlation between the incidence of MetS and helminth infections, suggesting that, as with 
autoimmune and allergic diseases, helminths may play a protective role against MetS disease. 
Within this review, we will focus primarily on the excretory-secretory products that the 
parasites produce to modulate the immune system and discuss their potential use as 
therapeutics against MetS and its associated pathologies. 
 
Introduction 
 
Metabolic syndrome (MetS), which presents as a cluster of conditions such as hypertension, 
abdominal obesity, high fasting plasma glucose and dyslipidemia, is associated with a greater 
risk of developing type 2 diabetes (T2D) and cardiovascular diseases (CVD) such as 
atherosclerosis, the leading causes of mortality worldwide. The underlying mechanisms of 
MetS are still not fully understood but it is notable that the majority of patients with the 
syndrome exhibit some degree of insulin resistance (IR). There are many factors that 
contribute to the development of IR, including obesity, physical inactivity, age, diet and 
genetic factors, with obesity and physical inactivity being the main driving force in most 
cases. Thus, the mechanisms by which obesity may contribute to metabolic dysfunction have 
been under intense investigation in recent years. Hotamisligil et al were the first to observe a 
significant increase in the levels of the pro-inflammatory cytokine TNF-D in obese mice, 
thereby linking inflammatory responses to obesity1. Chronic inflammation has since been 
found to be strongly associated with obesity and MetS - obese people with MetS have an 
increased level of circulating inflammatory markers such as C-reactive protein2 and there is 
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an increased incidence of cardiovascular diseases in patients with inflammatory diseases such 
as rheumatoid arthritis (RA)3. Under normal physiological circumstances, excess nutrients are 
processed and stored by professional metabolic tissues ± the liver, white adipose tissue 
(WAT) and skeletal muscle. In obese individuals, these tissues can become overloaded, 
resulting in an increase in free fatty acids in the tissues and circulation, leading to cellular 
metabolic dysregulation manifesting as mitochondrial dysfunction, oxidative stress and an 
increase in intracellular lipids. Obesity-induced cellular dysfunction results in the activation 
of a number of intracellular signalling pathways such as those involving mTOR, JNK and 
IKKE. In turn, these pathways converge and inhibit insulin signalling, primarily via serine 
phosphorylation of insulin receptor substrate (IRS) proteins, blunting insulin action in these 
tissues and leading to IR4.  
 
Intracellular signalling pathways involved in obesity and MetS 
 
The signalling cascade of PI3K/AKT/mTOR has a profound influence on cell survival5, 
regulation of insulin sensitivity/resistance and cell metabolism6. Specifically, the recently 
demonstrated ability of the mTOR inhibitor, rapamycin, to prevent insulin resistance in 
humans7 has highlighted this pathway as a point of intervention for MetS. The PI3K/AKT 
signalling cascade is activated by ligation of a range of receptors including G protein coupled 
receptors, B and T cell receptors and tyrosine kinase receptors such as the insulin and insulin 
like-growth factor 1 (IGF-1) receptor (Figure 1)8. The last two receptors stimulate IRS1 and 2 
to activate PI3K, which in turn results in the phosphorylation and activation of Akt9,10. In 
addition, the activation of the IIS (insulin/insulin like growth signalling) pathway leads to the 
up-regulation of mTOR complex 2 (mTORC2) and PDK1 activity, which are both required 
for the complete phosphorylation of Akt11. To date, Akt has been demonstrated to have 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
multiple roles: regulating mTORC1 activation, mediating cell survival via the suppression of 
apoptosis-associated proteins such as Bad12, inhibiting Fox0 transcription13, and regulation of 
NF-NB activity14. Reflecting this, in the context of insulin signalling, the activation of Akt is 
essential for the upregulation of mTORC1 activity (via the inactivation of tuberous sclerosis 
complex 1 and 2 (TSC1/2) and activation of S6 kinase (S6K))11. The mTOR complex is 
primarily conserved for nutrient sensing: thus, activation of mTOR can be mediated by 
environmental amino acids, fatty acids, glucose and hormones15, an important factor when 
one considers the mechanisms of insulin resistance (IR) in terms of MetS. Indeed, recent 
findings suggest that nutrition can impact on mTOR activation, demonstrating that calorie 
restriction can reduce activation of mTOR and prevent IR16. By contrast, a number of studies 
have demonstrated that over-activation of mTOR results in the formation of a negative 
feedback loop, whereby IRS-1 and IRS-2 are downregulated by S6K signalling17, thereby 
impairing insulin sensing. Thus, it is evident that mTOR deactivation is key to the control of 
IR and that nutrient/calorie restriction may have a role in regulating this.  
 
The stress-activated c-Jun amino-terminal kinase (JNK) and the inhibitor of N kinase (IKK) 
are proposed to be central mediators of obesity-associated inflammation and stress responses 
(reviewed by18). Certainly, expression of both of these kinases is increased in the liver, 
skeletal muscle and adipose tissue of obese mice and genetic ablation of JNK1 renders mice 
resistant to weight gain and metabolic pathologies19. Additionally, mice that are heterozygous 
for IKKE, an upstream activator of NF-NB, are protected from insulin resistance in both diet-
induced and genetic obesity20. These kinases are potentially activated by a number of 
pathways during obesity. For example, signalling via the Toll-like receptors (TLRs) of the 
innate immune system potently activates JNK and IKK and TLRs have also been shown to be 
upregulated in adipose tissues during obesity. Indeed, macrophages and adipocytes can be 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
activated to produce pro-inflammatory cytokines IL-6 and TNF-D after stimulation with 
saturated fatty acids (FAs) such as palmitate in a TLR4-dependent manner and knock-down 
of TLR4 reduces the activation of NF-NB in adipose tissue of obese mice21. Moreover, 
MyD88 is a key signalling adaptor molecule required by most TLRs that has also been shown 
to play a role in dysregulated signalling during obesity, as evidenced by targeted depletion of 
MyD88 in the CNS of mice protecting them from weight gain and leptin resistance22. 
Highlighting the role of TNFD downstream of TLR signalling, Hotamisligil and colleagues1 
have directly linked increased levels of TNF-D with insulin resistance and obesity whilst 
others23 have demonstrated that blockade of TNF-D signalling, via the genetic deletion of 
TNF-D and its two receptors TNFR1 and 2, reduces the incidence of IR in HFD-fed mice. 
This reflects that ligation of TNFR1 and 2 receptors can trigger the activation of MAPK and 
NFNB signalling25, thereby promoting pro-inflammatory cytokine release24 and indicating 
that, either via direct activity or synergistic mechanisms,  the TLR pathway is likely to 
contribute to the pathogenesis associated with in metabolic syndrome.  
 
Other innate immunity sensors like the NLRP3 (nucleotide-binding domain, leucine-rich-
containing family, pyrin domain-containing-3) inflammasome, activation of which leads to 
the cleavage of pro-caspase-1 and results in the production of mature IL-1E and IL-18, have 
also been demonstrated to play a critical role in the development of insulin resistance26. Thus, 
monocyte-derived macrophages from newly diagnosed, untreated type 2 diabetic patients 
show elevated expression of components of this inflammasome compared to healthy 
controls27. Moreover, a high-fat diet was found to induce caspase-1 activation in the AT of 
mice28, whilst ablation of NLRP3 improves insulin signalling in diet-induced obese mice and 
this is associated with a decrease in IL-1E in AT and reduced circulating IL-1829,30. IL-1E is 
one of the main cytokines to be implicated in the development of insulin resistance and 
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accordingly it has been shown that IL-1E-/- mice on a HFD do not exhibit IR30. Furthermore, 
saturated FAs such as palmitate and stearate, were shown to activate NLRP3 in macrophages 
in a ROS-dependent manner30. Collectively, this led to the proposal that the increased levels 
of glucose and fatty acids in the organs and circulation of obese individuals are recognised by 
the NLRP3 inflammasome as metabolic danger signals31. As the inflammasome can also be 
activated by molecules such as ceramides, ATP, oxidised LDL, uric acids and cholesterol 
crystals, all of which, along with FAs, are elevated in obesity and can increase ROS 
production, a prerequistite for NLRP3 signalling32, the NLRP3 inflammasome may be 
activated by a range of substances during obesity. Demonstrating the importance of NLRP3 
activation in obesity, Dalmas and colleagues33 found that IL-1E derived from adipose tissue 
macrophages (ATMs) from obese type 2 diabetic patients induces the expression of IL-22 
and IL-17 by adipose-resident CD4+ T cells. These cytokines, in turn, can further stimulate 
the production of pro-IL-1E in macrophages33 highlighting the interplay between tissue 
resistant cells and indicating that the local cytokine milieu should be considered during the 
development of inflammasome-centric treatments. Nonetheless, these findings strongly 
support the NLRP3 inflammasome as an attractive therapeutic target against obesity and 
MetS, and indeed treatment with the IL-1 inhibitor Anakinra, has been shown to improve E-
cell secretory functions and reduce systemic inflammatory markers CRP and IL-6 in T2D 
patients34. Together, these studies demonstrate that there are multiple signalling pathways 
that are activated in times of nutrient excess that contribute to the inflammatory response in 
obesity and that targeting of these pathways can be beneficial when it comes to novel 
treatments for patients with MetS. 
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Cellular composition of adipose tissue during obesity  
 
Activation of these inflammatory pathways and consequent recruitment of infiltrating cells 
has a profound effect on the cellular composition of white adipose tissues (WAT). For 
example, in lean mice adipose ATMs are predominantly of an Alternatively Activated 
Macrophage (AAM)/M2-like tissue protective phenotype characterised by expression of 
Arginase 1, chitinase (Ym1) and IL-10 production. Whilst the transcription factor peroxisome 
proliferator activator receptor-J (PPARJ) is required for maturation35 IRF5 appears to act to 
suppress accumulation of AAM in AT36 Inflammation during diet-induced obesity triggers 
adipocytes to secrete pro-inflammatory mediators such as IL-6, IL-ȕ 71)-Į 0,3V DQG
CCL-2 that recruit circulating macrophages into the tissue37,38, such that the number of 
macrophages in WAT positively correlates with increasing adiposity39. ATMs are known to 
play a key role in the inflammation associated with obesity. Although initially thought to be 
akin to M1-like inflammatory macrophages, a new subset of macrophages that lack 
expression of markers like CD38 and exhibit a distinct transcription profile, have recently 
been identified in adipose tissue and termed metabolically activated macrophages (MMe)40. 
These macrophages can be differentiated in vitro via stimulation with insulin, glucose and 
palmitate, stimuli mimicking the conditions present during obesity. MMes express ABCA1 
and CD36 and produce a host of pro-inflammatory cytokines and thus are phenotypically 
similar to ATMs found in human and murine adipose tissue40. Eosinophils have been 
demonstrated to be the major IL-4-producing cells in WAT and are essential for the 
maintenance of the AAM population in health41. In obesity, these cells are replaced by 
neutrophils and mast cells that help to generate the pro-inflammatory conditions in the WAT 
that are thought to contribute to IR. Additionally, it has recently been shown that the 
associated decrease in eosinophils in WAT is associated with a loss of group 2 innate 
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lymphoid cells (ILC2s), that have been reported to be important for the production of the IL-5 
and IL-13 that is required to sustain eosinophils and AAMs respectively in the WAT42. ILC2s 
have been detected in murine epididymal WAT and human subcutaneous fat and are 
decreased in both obese human donor adipose tissue and in the adipose tissue of mice fed a 
HFD43. By contrast, diet-induced obesity promotes the expansion of ILC1 cells that produce 
IFN-J, driving differentiation of pro-inflammatory macrophages44. Other lymphocyte 
populations undergo similar shifts in phenotype: thus, whilst in healthy adipose tissue IL-4-
producing TH2 cells and adipose-specific CD4+ FOXP3+ T regulatory cells are essential for 
metabolic homeostasis, during diet-induced obesity these cells are replaced with infiltrating 
inflammatory TH1 cells45,46. Similarly, infiltrating cytotoxic CD8+T cells have been 
demonstrated to arrive prior to M1 macrophages in adipose tissue and depletion of these cells 
results in reduced adipose inflammation and an improvement in glucose tolerance suggesting 
they may be pivotal in the initiation of inflammatory responses in obesity47. Studies utilising 
MHC Inull and MHC IInull mice revealed that B cells are crucial for the activation of CD4+ and 
CD8+ T cells in adipose tissue, and corresponding with this, B cellnull mice have improved 
insulin sensitivity when fed HFD48. However, adipose-specific IL-10-secreting B regulatory 
cells, recently identified by Nishimura et al49, have been found to reduce inflammation within 
adipose tissues of obese mice. Consistent with this, depletion of IL-10 from B cells increased 
the infiltration of M1 cells and CD8+ T cells in adipose tissue and transfer of IL-10 Bregs, but 
not splenic B cells, from lean mice to obese B cell KO mice decreases the secretion of IFN-J 
from CD8+ T cells49. These studies suggest that, as with macrophages, there is a delicate 
balance of effector B and T cell subsets present in the AT that exert positive and negative 
effects on the immune response. Overall, it can be stated that a TH2-biased, anti-
inflammatory immune profile promotes metabolic homeostasis in AT. 
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Parasites and associated immune responses 
 
Helminths, and the products they produce, are the most potent natural inducers of a type-2 
immune response. They typically prime T cells towards a TH2 phenotype characterised by 
the production of IL-4, IL-5 and IL-13, increase tissue eosinophil numbers, and prime B cells 
to generate high levels of IgE. In addition, helminths bias macrophages towards an AAM/M2 
phenotype and prime dendritic cells to induce TH2 responses. Helminths have co-evolved 
with humans for millennia and some are able to reside in individuals for decades without 
causing any severe pathology, which is beneficial not only to the parasite but also to the host. 
This is a result of their ability to modify the typical TH2 response with a regulatory 
component characterised by the presence of Breg and/or Treg cells, AAM/M2-like 
macrophages and the production of IL-10 and TGF-E cytokines and IgG4 antibodies50. One 
of the key mechanisms utilised by helminths to induce this immune phenotype is the 
production of excretory-secretory (ES) products which interact with and influence their host¶s 
immune system51,52. However, in the past fifty years, due to increased hygiene and 
advancement of medicines we have drastically reduced the rate of infectious diseases such as 
those associated with helminths in the developed world. By contrast, during this time, the rate 
of allergic, autoimmune and inflammatory conditions such as asthma, rheumatoid arthritis 
and MetS-associated diseases has increased. In attempting to link these observations together 
it is pertinent that helminth infections and their products can be utilised in murine model 
systems to treat allergic and autoimmune diseases and currently there are number of clinical 
trials in progress, or being planned, that utilise helminths in the treatment of a range of 
allergic and autoimmune diseases (reviewed by53,54).  
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Helminths are not alone in their ability to modulate the host immune response to create an 
optimum environment ± protozoan parasites, such as Leishmania and Toxoplasma, are able to 
LPSDLU WKHKRVW¶V LQLWLDOTH1 response and bias it towards a TH2 phenotype to benefit their 
own survival. Specifically, L. mexicana, which causes the development of non-healing 
cutaneous lesions during infection, can suppress TH1-associated production of IL-1255±57 by 
macrophages and DCs, and consequently can inhibit IFN-J production58. Further promoting 
this TH1-TH2 switch, products from the parasite can also significantly enhance IL-4 
production in the draining LN59. In addition, there is growing evidence to suggest that other 
intracellular protozoans such as Toxoplasma, Plasmodium and Trypanosoma species may 
also be capable of skewing host production of TH1/TH2 associated cytokines. Reflecting this, 
a number of studies have demonstrated that infection with P. chabaudi or T. cruzi have 
protective effects in the murine model of multiple sclerosis (MS), experimental autoimmune 
encephalomyelitis (EAE), during which both parasites trigger the upregulation of IL-27 
production, promoting a protective TH2 type phenotype60,61. To date, many of the 
mechanisms underpinning how these parasites manipulate the host cell machinery are yet to 
be defined. It is clear, however, that much like helminths, these intracellular parasites have 
evolved methods of steering the host immune response, possibly via the production of surface 
bound and/or excretory-secretory molecules.  
 
As inflammation has now been established as a significant underlying mechanism of MetS-
associated diseases it has recently been speculated that parasites may protect against MetS 
and this is supported by emerging evidence of an inverse correlation between helminth 
infections and incidence of MetS62. For example, Aravindhan et al examined the prevalence 
of filarial infection among diabetic, pre-diabetic and non-diabetic subjects in a cross-sectional 
study in India and reported a significant decrease in the incidence of filarial infection in 
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diabetic patients compared to non-diabetic subjects63. Consistent with this, helminth infection 
has been shown to be effective at reducing weight gain and improving glucose tolerance in 
obese mice. For example, Yang et al used both a genetic deficiency and a diet-induced model 
of obesity to demonstrate that infection with the gastrointestinal nematode Nippostronglyus 
brasiliensis caused less weight gain than that observed in wild-type littermates or uninfected 
mice on high-fat diet (HFD) respectively64. Likewise, chronic infection with the trematode, 
Schistosoma mansoni, decreased fat mass and adipocyte hypertrophy in HFD-fed mice, 
which were accompanied by improvements in whole-body glucose tolerance and insulin 
sensitivity65. Recently, it has additionally been demonstrated that infection with the filarial 
nematode Litomosoides sigmodontis improves glucose tolerance in diet-induced obese mice, 
and this is associated with an increase in eosinophils, AAM and CD4+ T cells in the 
epididymal AT66. Furthermore, S. mansoni infection has been demonstrated to reduce 
atherosclerotic lesion development in ApoE-/- mice67,68, a well-established model for the 
study of atherosclerosic lesion formation69, and this is consistent with a reduced frequency of 
atherosclerosis in schistosomiasis patients67.  
 
Perhaps providing a molecular rationale for this, it has also recently been demonstrated that 
parasites can directly affect the mTOR signalling pathway: Narasimhan et al found exposure 
of human monocyte-derived dendritic cells to Brugia malayi microfilarie (MF) to have a 
similar effect as treatment with Rapamycin in that it resulted in downregulation of 
phosphorylation of mTOR, p70S6K1 and 4EBP1 while also inducing autophagy in these 
cells, as evidenced by upregulation of phosphorylation of Beclin-1, induction of LC3II and 
degradation of p6270. Similarly, it has been demonstrated that L. major promastigotes express 
a surface metalloprotease, GP63 that is important for mediating parasite engulfment71, and 
which influences a number of key signalling molecules72 in the intracellular environment of 
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the macrophage. Most notably GP63 can inhibit mTORC1, consequently resulting in a 
blockade in phosphorylation of translational initiation factor 4E-BP173. This 
dephosphorylated state of 4E-BP1 causes suppression of macrophage protein synthesis74 and 
has been shown to be important for L. major parasite survival and replication. Moreover, it 
has been demonstrated that following infection, L. donovani-parasitised macrophages express 
lower levels of AKT75 which will have a profound downstream effect on mTORC1 activity. 
Indeed, the importance of mTOR activity in macrophages has recently been investigated, 
utilising macrophage specific mTOR null mice to demonstrate that in the absence of mTOR 
activity, HFD-fed mice exhibit a  reduced liver and adipose inflammatory gene expression 
profile76. These studies are of particular interest as very recent work has demonstrated that 
elevated dephosphorylated 4E-BP1 levels can protect against diet-induced obesity, insulin 
resistance and associated MetS77 while autophagy is known to play a key role in the 
suppression of production of inflammasome-associated cytokines IL-1E and IL-18 by 
stabilising mitochondria and preventing release of mitochondrial DNA into the cytoplasm78. 
As inhibition of the inflammasome or IL-1E has been demonstrated to prevent IR, targeting a 
regulator could represent a potential future therapy against diabetes and MetS. 
 
Currently, there is a great deal of ongoing work examining the effect of helminth infection on 
metabolic syndrome: however, the present review will examine in detail the potential of 
parasite products, in particular, excretory secretory products, to influence the immune system, 
and specifically, their effect on the metabolic syndrome.  
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Excretory-secretory products of parasites 
 
Helminths are able to modulate the host immune response to ensure their own survival. One 
of the main PHFKDQLVPVHPSOR\HGE\WKHVHSDWKRJHQVLVWKHUHOHDVHRI³H[FUHWRU\-VHFUHWRU\´
(ES) products that actively dampen the host immune response to the parasite. These products 
are a diverse mix of proteins, glycans, lipids and nucleic acids and while they may utilise 
different mechanisms, in general they induce a type 2/regulatory phenotype in the host (see 
Table 1). ES-62, a 62kDa glycoprotein, is the major ES protein of the rodent filarial 
nematode Acanthocheilonema viteae and is perhaps the best characterised of all the secreted 
helminth products. ES-62 contains the unusual post-translational modification of 
phosphorylcholine (PC) moieties attached via an N-linked glycan79,80, and this feature appears 
to be responsible for the majority of the anti-inflammatory effects of ES-6281,82. These effects 
include priming DCs towards a TH2 phenotype; inhibiting macrophage and mast cell 
activation; promoting induction of B regulatory cells and inhibiting TH1 and TH17 
polarisation (reviewed in83). Similarly, S. mansoni soluble egg antigen (SEA) which contains 
ES products, skews the host immune response to the worm from an inflammatory TH1 to a 
TH2 phenotype. DCs treated with SEA in vitro are polarised to prime TH2 responses and are 
refractory to TLR stimulation84 while macrophages treated with one of the components of 
SEA, LNFPIII, a trisaccharide LewisX-containing glycan, differentiate fully into an 
alternatively activated phenotype with upregulated expression of CD301, Ym1 and Arg1 and 
produce IL-1085. In vivo administration of ES products is sufficient to induce a strong TH2 
response ± for example, ES from adult N. brasiliensis (NES) induces a strong TH2 response, 
even in the presence of the TH1/TH17 polarising agent, complete FreunG¶V DGMXYDQW86. 
Helminth ES products from a variety of species have also been found to be therapeutic in 
multiple mouse models of inflammatory disease including collagen-induced arthritis (CIA), 
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type 1 diabetes (T1D), experimental autoimmune encephalomyelitis (EAE), colitis, and 
asthma and other allergies (reviewed in52). As discussed, MetS is associated with chronic 
inflammation and thus, given their potent anti-inflammatory effects, and therapeutic potential 
in inflammatory diseases it seems likely that helminth ES products could have a significant 
impact on MetS. 
 
Protozoan parasites also produce a range of secreted products that influence the host to ensure 
their own survival. One of the best studied molecules constitutes a group of cysteine 
proteases (CPs) produced by L. mexicana87. It has been demonstrated that this highly active 
group of Cathepsin-L like proteases are primarily produced by the amastigote (intracellular 
form of parasite)88 and their role as a key virulence factor during infection has been 
confirmed in a number of studies through the use of a variety of CP mutant promastigotes55. 
Further evidence suggests that the most abundantly expressed form of L. mexicana specific 
CP, CPB2.8 can drive a TH2 response in vivo. Pollock et al have demonstrated that 
administration of purified recombinant CPB2.8 can stimulate both IL-4 and IL-5 production 
in the draining lymph node and can enhance circulating IgE titres59. The mechanisms 
underpinning these findings remain unclear, however it should be considered that, the CPs 
are similar in structure to other allergy-inducing proteases such as dust mite derived DerpI, a 
potent inducer of IL-4 and IgE89. Thus, it is perhaps unsurprising that CPB2.8 is so effective 
in polarising the immune response from a TH1 dominated healing response, to a TH2 
dominated chronic phentotype. Hence, these Leishmania secreted CPs represent a group of 
potentially novel immunomodulatory molecules.  
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Helminth ES and MetS 
 
The strong TH2 response generated in response to SEA and LNFPIII led Bhargava et al to 
investigate whether these products have any effect on chronic inflammation with respect to 
obesity and subsequently improve metabolic function in HFD-fed mice. Injection of either for 
4-6 weeks after the onset of obesity in HFD-mice augmented the production of IL-10, as well 
as increasing insulin sensitivity85. Unlike with live helminth infection65, neither treatment had 
any effect on body weight or circulating lipid or adiponectin concentrations85. However, both 
LNFPIII and SEA had significant effects on the cell composition/interactions in the WAT ± 
there was a decrease in the number of observed crown-like structures (CLS), and the gene 
expression of inflammatory genes such as TNF-D, Casp1, nlrp3, il18 and il1E was reduced 
with a corresponding increase in il10 and the M2 genes Arg1 and MgL185. It has recently 
been demonstrated that SEA mediates this improvement in metabolic homeostasis by 
restoring the type 2 response in the WAT through the induction of eosinophil recruitment65, 
which has previously been shown to be crucial in promoting the presence of M2 
macrophages41. Correspondingly, SEA shifts the M1/M2 ratio towards an M2 phenotype, and 
increased the numbers of IL-4+, IL-5+ and IL-13+ CD4+ T cells in gonadal WAT65. In keeping 
with improved insulin sensitivity there was also an increase in insulin receptor B, insulin 
receptor substrate 2, C/ebp-D and glucose transporter 4 gene expression in the WAT of 
LNFPIII-treated mice. These effects are not due to direct effects of LNFPIII on adipocytes: 
they appear to be mediated indirectly via production of IL-10 by macrophages as conditioned 
medium from LNFPIII-primed macrophages from WT but not IL-10-/- mice improved insulin 
responsiveness in 3T3-l1 adipocytes85. SEA and LNFPIII were also demonstrated to have a 
strong protective effect on diet-induced hepatic steatosis, with treated HFD-mice exhibiting 
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reduced serum levels of the triglycerides, AST and ALT as well as decreases in genes 
associated with lipogenesis such as Srebp, in the liver85. 
 
Of interest, while not a secreted helminth product, L. sigmodontis antigen (LsAg) has also 
been demonstrated to mediate some protection against MetS, as therapeutic administration of 
LsAg for a two-week period improves glucose tolerance in diet-induced obese mice. This 
protection was found to require eosinophils but to be independent of CD4+FOXP3+ T cells66. 
Treatment of the pre-adipocyte cell line (3T3-L1) with LsAg was found to inhibit their 
differentiation into mature adipocytes suggesting LsAg may also be able to suppress 
adipogenesis66. It will therefore be interesting to see whether Ls ES products have similar 
properties. 
  
Helminth ES and Atherosclerosis 
Atherosclerosis is a lipid-driven disease of the arteries, caused by lipid deposition and intimal 
thickening of the aorta and larger arteries, characterised by sustained inflammatory responses 
and specifically, the chronic activation of macrophages90,91. MetS significantly increases the 
risk of atherosclerosis, which is one of the main underlying pathologies for cardiovascular 
diseases such as stroke and myocardial infarctions, as alluded to earlier, the leading cause of 
death in the Western world92. Wolfs et al demonstrated that weekly treatment with SEA 
resulted in a 44% reduction in atherosclerotic plaque size in a cholesterol-induced murine 
model of atherosclerosis91. This was associated with a significant decrease in circulating 
inflammatory monocytes, as well as reduced plaque necrosis and inflammation, and reduced 
gene expression of CD68, TNF-D and MCP-1 in the aortic arch91. Chronic exposure to SEA 
has also been shown to cause a 30% reduction in plasma serum cholesterol and LDL levels in 
ApoE-/- mice fed a high-fat diet93, however there was no effect on lesion size or 
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inflammation, a perhaps surprising observation which the authors speculated could be a result 
of using dead eggs and heat-treated SEA in this study93.  
 
ES-62¶VDQWL-inflammatory properties dictate that it can protect against inflammatory diseases 
in models such as collagen-induced arthritis and the MRL/lpr model of systemic lupus 
erythematosus94±96. Patients with these diseases are at greater risk of developing 
atherosclerosis and thus the protective effect of ES-62 was investigated in gld.ApoE-/- mice, 
that are commonly utilised as a model for the study of the accelerated cardiovascular disease 
that can occur in some lupus patients97. When treated with ES-62, via osmotic pumps for 12 
weeks to release ES-62 at a steady rate and mimic natural infection, these mice demonstrated 
reduced atherosclerotic lesion area of nearly 60% compared to PBS-treated mice, with 
reduced numbers of macrophages and collagen at the lesion site. Similar to studies in the 
MRL/lpr mouse, they also had some evidence of reduced renal disease as measured by 
decreased proteinuria, as well as decreased levels of the anti-nuclear antibodies (ANA) that 
contribute to kidney disease98. 
  
Can other parasite molecules influence the outcome of MetS? 
 
The seminal work carried out by Bhargava (2012) has shown that modulation of 
inflammatory responses by a parasite-derived product can significantly impact on the 
outcome of MetS in obese mice85. Specifically, it has been shown that suppression of M1 
inflammatory responses and polarization towards an M2 phenotype are advantageous in the 
fight against metabolic disease, therefore suggesting the parasite products that influence 
M1/M2 polarisation during chronic parasite infection may provide a potential novel therapy 
for treatment or prevention of MetS. It is interesting to speculate therefore that other parasite 
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products with the ability to influence the differentiation of macrophages may also have the 
potential to be therapeutic in MetS. With this is mind, it is of particular interest that the 
intracellular protozoan T. gondii, has been shown to utilise some of its key proteins conserved 
for cellular invasion to do just that. Rhoptry proteins (ROPs) are secreted from the apical 
complex during the process of host cell entry and are either released into the host cytosol or 
retained at the parasitophorous vacuole membrane (PVM). Recently, a number of studies 
have demonstrated how ROPs, specifically ROP16 (in Type I/III strains of T. gondii) can 
target host transcription and cause prolonged phosphorylation of STAT3 and STAT6, 
resulting in the suppression of IL-12 production99,100. Further to this, ROP16-mediated 
STAT6 activation has also been associated with enhanced levels of arginase-1 production, in 
both macrophages and fibroblasts. Thus, the secreted ROP16 appears to be instrumental in 
ablating TH2 suppressive cytokine production and also promoting M2 macrophage 
polarization101. Moreover, ROPs do not appear to be the only protozoan products to exhibit 
this effect: for example, a T. gondii-specific peroxiredoxin (Prx) known as rTgPRx102, which 
has recently been shown to be a potent anti-inflammatory molecule103, appears to promote 
development of an AAM phenotype via STAT6-dependent and -independent enhancement of 
arginase-1 and YM1 expression. In addition, the recombinant protein has been shown to 
stimulate the expression of IL-10 to further reinforce the regulatory/TH2 type response. 
These marked effects of the protozoan Prx may not be so surprising as a number of studies 
had previously demonstrated the effectiveness of Prxs derived from the helminths S. mansoni 
and Fasciola hepatica, in similarly driving alternative activation of macrophages in vivo. 
Thus, treatment of BALB/c mice with recombinant F. hepatica Prx, induces Ym1 expression 
in peritoneal macrophages, and increases circulating titres of IL-4104,105. Additionally, as 
mentioned previously, various ES products from several helminth species stimulate 
alternatively activated macrophages: thus, ES-62-treated macrophages are refractory to LPS-
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induced pro-inflammatory cytokine production106 and treatment of macrophages with SEA 
induces an anti-inflammatory profile with decreased levels of LPS-induced IL-12 and TNF-D 
and increased IL-10 production91.  
 
Targeting other relevant inflammatory mediators 
 
It has recently been demonstrated that ES-62 interacts, via its PC moieties, with CRP in 
human serum107. This interaction does not result in activation of the complement cascade 
because the ES-62-CRP-C1q complex generated appears to be unable to efficiently cleave 
C2. In this way ES-62 secreted by the parasite during infection can provide some protection 
against the activation of complement, thus preventing parasite opsonisation. However, it also 
further demonstrates the ability of ES-62 to dampen inflammatory responses, in this case 
CRP-dependent that may play an important role in conditions that represent medical 
emergencies such as myocardial infarction and stroke. Furthermore, PC binding to CRP has 
recently been demonstrated to bias migrating monocytes and T cells towards an M2 and TH2 
phenotype respectively in an in vitro model108 and therefore it is possible that ES-62 by 
binding to CRP may also have this capability. 
 
We have previously discussed the importance of NLRP3 inflammasome activation in driving 
inflammation and disease during MetS and therefore, molecules with the ability to suppress 
such responses could provide a potential therapeutic for the syndrome. For example, 
treatment of human macrophages with F. hepatica helminth defence molecule 1 (FhHDM-1), 
a cathelicidin-like molecule secreted by the parasite, significantly reduces their production of 
IL-1E in response to phagocytosis of Alum particles109 while a small molecule analogue 
(SMA) of ES-62 (based on its PC moiety), SMA 12b, has been found to mediate its 
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protective effects in the CIA model via suppression of NLRP3 activation and decreased IL-
1E production110. The protozoan product rTfPRx suppresses macrophage ROS production via 
modulation of NLRP3 inflammasome activation and is capable of inhibiting both caspase-1 
and IL-1E production following LPS-stimulation of the inflammasome103. Finally, 
Leishmania-derived, GP63 also appears to modulate activation of the NLRP3 inflammasome, 
suppressing the production of IL-1E, both during infection and, importantly, in macrophages 
treated with purified GP63111. These modulators all exhibit potential as modifiers of the 
NLRP3 inflammasome pathway and as such are exciting candidates for the basis of future 
therapeutics. 
 
As mentioned earlier in the review, MyD88 appears to be a crucial integrator of TLR and 
inflammasome signals impacting on obesity and MetS112, and one of the key mechanisms of 
ES-62 in its protection in CIA and lupus models is the degradation of MyD8895,96. 
Interestingly, ES-62 has also been demonstrated to strongly suppress the basal levels of active 
Akt in DCs in vitro in a TLR4-dependent manner81 thus suggesting that it can target multiple 
layers of the pathways necessary to reduce the damaging pro-inflammatory immune response 
generated during MetS. 
 
Conclusions 
 
Inflammation associated with MetS has now been established to be central to the 
development of insulin resistance and cardiovascular disease. During obesity, the cellular 
composition of adipose tissue changes from an anti-inflammatory/TH2 environment 
characterised by M2, eosinophils, TH2 CD4+ T cells and Bregs to a pro-inflammatory 
environment characterised by higher numbers of M1, neutrophils, mast cells, TH1 and 
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cytotoxic CD8+ T cells. Throughout this review we have discussed the host immune 
regulation that helminths and protozoans can elicit during infection and the secretory 
molecules that these parasites use to exert these effects, particularly their ability to drive a 
TH2 response while suppressing an opposing inflammatory phenotype. Therefore, it is 
possible that helminth- and protozoan-derived molecules that enhance protective anti-
inflammatory responses, such as Type 2 immunity, alternative activation of macrophages and 
modulation of mTOR signalling could be beneficial in the treatment of metabolic disorders 
(Figure 2). 
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Figure Legends 
 
Figure 1: The role of PI3K/Akt, mTORC1, mTORC2, and the NLRP3 inflammasome in the 
development of metabolic syndrome. A schematic detailing the key signalling molecules and 
pathways activated/supressed during nutrient excess, insulin resistance and associated chronic 
inflammation. 
 
Figure 2: Parasitic ES products are able to influence a range of signalling pathways such as 
PI3K/Akt and the inflammasome, as well as biasing immune system cells towards a type 2 
phenotype, both of which suggest they may be able to provide protection against MetS. 
 
Table 1: The mechanisms of action of some of the best characterised parasite-derived 
excretory-secretory products on the immune system and in murine disease models is 
summarised. 
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Table 1 
  
Parasite 
excretory-
secretory 
product 
Immune responses affected Animal disease model References 
A. viteae ES-62 
Downregulates MyD88 to subvert TLR-
mediated activation of macrophages, DCs and 
mast cells in a TLR4-dependent manner; 
resets macrophage and TH1/TH2/TH17 
homeostasis; inhibits B2 cell activation and 
induces IL-10-secreting B1 cells and various 
Breg populations 
Collagen-induced arthritis (CIA); 
ovalbumin-induced airway 
hypersensitivity; oxazolone-induced 
contact sensitivity, MRL/lpr model of 
SLE, Gld.ApoE-/- model of lupus-
associated accelerated atherosclerosis 
12,83,95,96,98,113, 
131,14 ,141,15 
S. mansoni SEA 
Priming of DCs towards a TH2 phenotype, 
induction of TH2 cells in vivo, induction of 
Tregs 
Experimental Autoimmune 
Encephalomyelitis (EAE); Type 1 
Diabetes (T1D) in non-obese diabetic 
(NOD) mice; CIA; glucose tolerance in 
HFD-fed mice; cholesterol-driven 
model of atherosclerosis 
18,85,116±119 
S. mansoni LNFPIII Induction of AAM phenotype; priming of DCs towards a TH2 phenotype 
glucose tolerance in HFD-fed mice; 
psoriasis; T1D; EAE 20,85,116,120,121 
F. hepatica ES 
Priming of DCs to induce TH2 and Treg 
responses; induction of AAMs; inhibition of 
TH17 responses in vivo 
T1D in NOD mice; CIA 24,122±125 
F. hepatica HDM-1 induction of AAM; inhibition of NLRP3 inflammasome activation in macrophages 
murine models of T1D and multiple 
sclerosis 25,124,126 
F. hepatica 
peroxiredoxin Induction of AAM not tested 04105 
N. brasiliensis ES Induction of TH2 cells in vivo via DC priming allergic lung inflammation 27,86,127,128 
H. polygyrus ES 
Inhibition of TH1 responses; inhibition of 
macrophage NO production; inhibition of 
PAMP-mediated DC responses 
not tested 50,51 
L. mexicana CPB2.8 Induction of TH2 response in vivo, induction 
of IgE not tested 58,59 
T. gondii Rhoptry 
proteins 
Suppression of IL-1; enhanced arginase-1 in 
macrophages and fibroblasts not tested 100,101 
T. gondii 
peroxiredoxin 
Induction of AAM; stimulation of IL-10; 
inhibition of macrophage ROS and IL-ȕ
production via inhibition of NLRP3 
inflammasome activation 
not tested 102,103 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
